“ (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a late-stage trial studying it as an add-on treatment for schizophrenia, sending its shares down nearly 7% in after-market trade.
The drug was approved last year, making it the first new type of antipsychotic medicine in decades. Bristol Myers obtained the drug, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics.”
Maybe put that $7 billion (7% of $100B market cap) towards Anavex Life Sciences to boost 3-71 development! 🤷🏻♂️
Golly! With the combined possibilities for Blarcamesine and 3-71, Sigmaceptor™️ just keeps looking better and better!
Bullish
Market Data 
Markets 
AI
